These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 23188051)
1. In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. Castellanos E; Rosas I; Solanes A; Bielsa I; Lázaro C; Carrato C; Hostalot C; Prades P; Roca-Ribas F; Blanco I; Serra E; Eur J Hum Genet; 2013 Jul; 21(7):769-73. PubMed ID: 23188051 [TBL] [Abstract][Full Text] [Related]
2. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Pros E; Fernández-Rodríguez J; Canet B; Benito L; Sánchez A; Benavides A; Ramos FJ; López-Ariztegui MA; Capellá G; Blanco I; Serra E; Lázaro C Hum Mutat; 2009 Mar; 30(3):454-62. PubMed ID: 19241459 [TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype Catasús N; Rosas I; Bonache S; Negro A; Torres-Martin M; Plana-Pla A; Salvador H; Serra E; Blanco I; Castellanos E; Mol Ther Nucleic Acids; 2022 Dec; 30():493-505. PubMed ID: 36420221 [TBL] [Abstract][Full Text] [Related]
4. [Mutation analysis of NF2 gene and clinical investigation in a Chinese family with neurofibromatosis type II]. Cui YX; Xia XY; Huang TT; Wei L; Fan XB; Yao B; Ge YF; Li XJ; Huang YF Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Dec; 27(6):688-91. PubMed ID: 21154335 [TBL] [Abstract][Full Text] [Related]
5. NF2: the wizardry of merlin. Xiao GH; Chernoff J; Testa JR Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860 [TBL] [Abstract][Full Text] [Related]
6. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. Baser ME; Kuramoto L; Woods R; Joe H; Friedman JM; Wallace AJ; Ramsden RT; Olschwang S; Bijlsma E; Kalamarides M; Papi L; Kato R; Carroll J; Lázaro C; Joncourt F; Parry DM; Rouleau GA; Evans DG J Med Genet; 2005 Jul; 42(7):540-6. PubMed ID: 15994874 [TBL] [Abstract][Full Text] [Related]
7. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma. Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203 [TBL] [Abstract][Full Text] [Related]
9. Can manipulation of splicing offer gene therapy possibilities to those with tumour-prone disorders? Evans DG; Wallace A; Newman W Eur J Hum Genet; 2013 Jul; 21(7):701-2. PubMed ID: 23188050 [No Abstract] [Full Text] [Related]
10. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154 [TBL] [Abstract][Full Text] [Related]
11. Current progress in genomics and targeted therapies for neurofibromatosis type 2. Hiruta R; Saito K; Bakhit M; Fujii M Fukushima J Med Sci; 2023 Aug; 69(2):95-103. PubMed ID: 37468280 [TBL] [Abstract][Full Text] [Related]
12. Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes. Abo-Dalo B; Kutsche K; Mautner V; Kluwe L Genes Chromosomes Cancer; 2010 Feb; 49(2):171-5. PubMed ID: 19924781 [TBL] [Abstract][Full Text] [Related]
13. Novel neurofibromatosis type 2 mutation presenting with status epilepticus. DiFrancesco JC; Sestini R; Cossu F; Bolognesi M; Sala E; Mariani S; Saracchi E; Papi L; Ferrarese C Epileptic Disord; 2014 Mar; 16(1):132-7. PubMed ID: 24667735 [TBL] [Abstract][Full Text] [Related]
14. CNS Young Investigator Award Lecture: molecular analysis of the neurofibromatosis 2 tumor suppressor. MacCollin M Brain Dev; 1995; 17(4):231-8. PubMed ID: 7503383 [TBL] [Abstract][Full Text] [Related]
15. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain. Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996 [TBL] [Abstract][Full Text] [Related]
16. Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus. Sainio M; Jääskeläinen J; Pihlaja H; Carpén O Neurology; 2000 Mar; 54(5):1132-8. PubMed ID: 10720287 [TBL] [Abstract][Full Text] [Related]
17. Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Schulz A; Baader SL; Niwa-Kawakita M; Jung MJ; Bauer R; Garcia C; Zoch A; Schacke S; Hagel C; Mautner VF; Hanemann CO; Dun XP; Parkinson DB; Weis J; Schröder JM; Gutmann DH; Giovannini M; Morrison H Nat Neurosci; 2013 Apr; 16(4):426-33. PubMed ID: 23455610 [TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of patients with neurofibromatosis 2. MacCollin M; Ramesh V; Jacoby LB; Louis DN; Rubio MP; Pulaski K; Trofatter JA; Short MP; Bove C; Eldridge R Am J Hum Genet; 1994 Aug; 55(2):314-20. PubMed ID: 7913580 [TBL] [Abstract][Full Text] [Related]
20. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]